enGene Therapeutics Inc. (ENGN): Shareholders' Equity
$167.71M
As of 2025-10-31
$230.29M
As of 2026-07-31
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-10-31 | $167.71M | -38.5% | 2025-12-22, Balance as of period end |
| 2024-10-31 | $272.61M | +276.1% | 2025-12-22, Balance as of period end |
| 2023-10-31 | $72.49M | n/m | 2024-12-19, Balance as of period end |
| 2022-10-31 | -$76.61M | n/a | 2024-01-29, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | $167.71M | -38.5% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $158.60M | -32.5% |
| Compass Therapeutics, Inc. (CMPX) | 2025-12-31 | $196.79M | +57.1% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $158.94M | -1.5% |
| Agenus Inc (AGEN) | 2025-12-31 | -$271.11M | n/m |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $123.12M | -48.9% |
| Solid Biosciences Inc. (SLDB) | 2025-12-31 | $180.01M | +31.2% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $168.77M | +516.2% |
| Protara Therapeutics, Inc. (TARA) | 2025-12-31 | $196.41M | +17.5% |
Compare ENGN, MGX, CMPX, IPSC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗